Welcome to our dedicated page for Novaccess Global news (Ticker: XSNX), a resource for investors and traders seeking the latest updates and insights on Novaccess Global stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Novaccess Global's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Novaccess Global's position in the market.
NovAccess Global (OTCQB:XSNX), a biomedical company, has filed a provisional patent with Cedars-Sinai for a new immunotherapy platform targeting brain tumors. The patent focuses on the IDH1 protein, which aids in cellular metabolism, predicting patient responses to treatments like glioblastoma. Research led by Dr. Chris Wheeler of StemVax, a NovAccess subsidiary, reveals IDH1's role in distinguishing long-term survivors post-vaccine therapy. This filing doubles the company's patent portfolio and aims to support the development of IDH1 and TLR-AD1, an FDA-designated Orphan Drug for malignant brain tumors. NovAccess plans to meet with the FDA to co-develop these technologies, hoping to improve treatment outcomes and life expectancy for brain cancer patients.
NovAccess Global Inc. (XSNX) has postponed its Annual Meeting of Shareholders scheduled for May 2024. The company plans to reschedule the meeting soon after announcing a virtual meeting for shareholders on May 6th, 2024.
NovAccess Global Inc. (OTCQB:XSNX) has obtained a new intellectual property license from Cedars-Sinai Medical Center to enhance its immunotherapy platform for central nervous system cancer patients. The license focuses on using Isocitrate Dehydrogenase-1 (IDH1) to predict patient responses to vaccine immunotherapy for malignant brain tumors like glioblastoma. This breakthrough research by Dr. Chris Wheeler aims to improve therapeutic strategies and patient outcomes for brain cancer treatment.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.